IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Graham P. Allaway, et al.

Serial No.: Not Yet Known (continuation of U.S. Serial No. 08/831,823, filed April 2, 1997)

Filed June 25, 2001

METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ For

CELLS

1185 Avenue of the Americas New York, New York 10036

June 25, 2001

Assistant Commissioner for Patents

Washington, D.C. 20231

Box: Patent Applications

SIR:

PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the specification:

On page 1, lines 1-5, please delete the paragraph which begins "This application claims priorty of U.S. Provisional" and insert the following paragraph:

-- This application is a continuation of U.S. 08/831.823. filed April 2, 1997, which claims priority of U.S. Provisional Application No. 60/019,715, filed June 14, 1996, and U.S. Provisional Application No. 60/014,532, filed April 2, 1996, the contents of which are incorporated by reference into this application . - -

In the claims:

Please cancel claims 1-50 without prejudice or disclaimer to

Applicants : Graham P. Allaway, et al.

U.S. Serial No: Not Yet Known Filed : June 25, 2001

Page 2

applicants' right to pursue the subject matter of these claims in a later-filed application and please add new claims 51-56 as follows:

--51. (New) An antibody or portion of an antibody capable of binding to a chemokine receptor on the surface of a CD4+ cell.--

- --52. (New) The antibody or portion of an antibody capable of binding to a CCR5 chemokine receptor on the surface of a CD4+ cell.--
- --53. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a PM-1 cell.--
- --54. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a primary CD4+ T-cell.--
- --55. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a PMBC cell.--
- --56. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the antibody is a monoclonal antibody.--

Remarks

Claims 1-50 are pending in the subject application. Applicants have hereinabove canceled claims 1-50 without prejudice or disclaimer to their right to pursue the subject matter of these claims in a later-filed application and added new claims 51-56. Support for newly added claims 51-56 may be found inter alia in the specification as follows: claim 51: page 4, lines 22-23; page 16, line 34; claim 52: page 11, lines 21-23; claim 53: page 26, table

Applicants : Graham P. Allaway, et al.

U.S. Serial No: Not Yet Known Filed: June 25, 2001

Page 3

-112

1; claim 54: page 30, lines 17-18; claim 55: page 33, lines 5-6; claim 56: page 28, line 25. This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully requested, such that claims 51-56 will be pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.

No fee, other than the enclosed \$490.00 filing fee, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White Registration No. 28,678 Spencer H. Schneider Registration No. 45,923 Attorneys for Applicant(s)

Actorneys for Applicanc(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400